本頁只刊出中文翻譯與中文說明；英文原文請見下方原文連結。
原文連結
論文資訊
- 類型：已發表論文
- 日期：2021-03-03
摘要
The regulatory process for market authorization of medical diagnostic and therapeutic products is fraught with ethical dilemmas that regulators outside the medical industry do not face. The consequences of approving an ineffective therapy with potentially dangerous side effects (a “Type I error” or false positive) must be weighed against not approving a safe and effective therapy (a “Type II error” or false negative) that could help ease the burden of 疾病 for many patients. Regulators must strike the proper balance by considering multiple factors, including scientific merit, clinical evidence from randomized control trials, the burden of 疾病, the current standard of care and alternatives, and patient preferences. How these factors are—and should be—weighed is not always clear, which only enc
※ 此為已發表論文，全文需透過期刊付費取得